Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Zoledronic Acid in Multiple Myeloma Bone Lesions
NCT00242528Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Apr 2004
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of zoledronic acid in multiple myeloma (MM), sponsored by Novartis. Planned start Apr 2004; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00242528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242528.